Citation | Chris Abell has made several fundamental contributions to biological chemistry, including pioneering detection of covalent intermediates on enzymes by mass spectrometry, and providing the first structural evidence for an ester linkage in a protein backbone. He has used his unique scientific insight and technological innovation to co-found several companies, most notably Astex (1999), Sphere Fluidics (2010) and Aqdot (2013). Using Fragment-Based Drug Discovery (FBDD), Astex has already developed 8 drug candidates that are now in human trials. FBDD has been adopted by almost every major pharmaceutical company in the world, literally changing the way drugs are discovered |